potassium phosphates in sodium chloride
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (potassium phosphates in sodium chloride) by Amneal Pharms is tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization. First approved in 2024.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
Potassium phosphates in 0.9% sodium chloride is an intravenous electrolyte replacement solution that restores critical phosphate and potassium levels in patients with deficiencies. It works by replenishing essential minerals involved in nucleic acid structure, energy storage, cell signaling, and bone mineralization. This product addresses acute electrolyte imbalances in hospitalized and critically ill populations.
Recent 2024 approval positions this as an emerging IV electrolyte product with expanding institutional demand and team-building opportunities in commercial and medical affairs.
tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This newly approved IV electrolyte product creates early-stage career opportunities in hospital-focused commercial teams, institutional affairs, and medical education. Professionals joining now will build expertise in critical care market access, physician relationships, and hospital formulary management during a growth phase.
Worked on POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo